CRTX News and Press, Cortexyme Inc. From 02/10/20

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat Alzheimer’s and other degenerative diseases, today announced that it has closed its private placement offering. The Company issued 2,500,000 sha...

Alzheimer's disease ranks among the most pressing medical needs facing the world. Because of the millions of aging baby boomers, the Alzheimer's Association anticipates the disease's frequency to soar from 5.8 million patients in the U.S. in 2019 to nearly 14 million by 2050. Deaths due to Alzhe...

Gainers: Unisys (NYSE: UIS )  +44% . More news on: Unisys Corporation, JanOne Inc., Intelsat S.A., Stocks on the move, , Read more ...

Thinly traded Cortexyme ( CRTX +24.7% ) is up in early trade, albeit on below-average volume of only 50K shares, on the heels of its $125M private placement of stock to a group of institutional investors and an entity affiliated with a board member. More news on: Cortexyme, Inc., Healt...

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat Alzheimer’s and other degenerative diseases, today announced that it has entered into stock purchase agreements with a group of institutional in...

-- Data in aged dogs shows oral dosing of COR388 results in target engagement, reduction of bacterial load and beneficial effects on downstream pathology -- Lysine-gingipains from P. gulae were found in the neurons of aged dogs, paralleling the discovery of gingipains from P. gingival...

  – Open-label extension study will provide COR388 to patients for an additional 48 weeks – GAIN Trial to continue as planned following pre-specified DMC safety data review Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a n...

– Corporate presentation by CEO Casey Lynch will be webcast live – Lynch will also participate in a roundtable session earlier in the day Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approac...

Gainers:  Marinus Pharmaceuticals (NASDAQ: MRNS ) +42% . More news on: Marinus Pharmaceuticals, Inc., Prothena Corporation plc, Applied Genetic Technologies Corporation, Stocks on the move, Read more ...

– In a Phase 1b trial, COR388 reduced levels of fragmented ApoE protein in cerebrospinal fluid of subjects with Alzheimer’s – –The drug’s target, the gingipains from P. gingivalis bacteria, preferentially attack the protein encoded by an APOE genetic va...